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MATERIALS AND METHODS
drugs is isoproterenol, probably because it has been available for approximately 25 years. Potential problems with the use of aerosol bronchodilator drugs include pharmacologic side effects, toxicity of the products of metabolic breakdown, and toxic effects of the diluting fluids, propellants such as Freons, and preservatives. Also, one can encounter infections from contaminated aerosol apparatus, psychic dependence upon aerosol treatment, and allergic reactions to bronchodilator drugs. The possible development of tolerance and the inadequate medication due to improper techniques of inhalation should be ~onsidered.'.~,~.~ This study was performed to determine the effectiveness and safety in human subjects of a form of metaproterenol not yet available in the United States. It has been available as a metered-dose inhaler, as 20-mg tablets and, more recently, as a syrup providing a dosage of 10 mg/5 ml. We studied ' Twenty-seven patients (15 female and 12 male patients) between the ages of 15 and 70 years with at least partially reversible asthma were studied. Six patients also had acute or chronic bronchitis. The duration of the asthma varied from 1 to 25 years. According to the frequency of asthmatic attadis, the medication required (ie, pro re nata vs every six hours), the disability produced by asthma, and the emergency-room visits or inpatient hospitalization, eight patients had severe asthma, 17 patients had moderate asthma, and two patients had mild asthma. Four patients finished the study but were excluded because we were unable to test pulmonary function during the crossover studies owing to equipment failure.
To qualify for the study, all patients had to show that their hcreased airway resistance responded to administration of sympathomimetic bronchodilator drugs with at least a 15-percent increase in the forced expiratory volume at one second (FEWl ) after a test dose of 0.15 mg of isoproterend sulfate administered by a metereddose inhaler ( MedihalerLo). The measurements of FEVl were taken at 15-minute intervals during the 90 minutes after administration. Before the qualifying test dose was administered, a complete history was taken, and a complete physical examination was performed. Patients with cardiac disease, hypertension, hepatic disease, hyperthyroidism, pregnancy, or a history of intderance to adrenergic drugs were excluded from the study. In addition, all patients admitted had normal findings on laboratory tests, including a complete blood cell count, urinalysis, and determinations of senun levels of urea nitrogen, glucose, uric acid, total protein, albumin, calcium, phosphorus, alkaline phosphatase, total bilirubin, glutamic oxaloacetic transaminase, lactic dehydrogenase, and oholesterol at the start and the end of the study.
Concomitant medication was allowed in the minimum amounts required for the patient's comfort and safety. No other aerosol bronchodilator was used. Corticosteroids were maintained at essentially constant dose levels during the study. Thirteen patients received oral therapy with corticesteroids, 23 patients received oral therapy with bronchodilator drugs, and 15 used oral or parenteral preparations of antihistamines. On the days of the double-blind orossover studies and on the qualifying day prior to admission to the study, no bronchodilator drug was taken for at least eight hows before testing of pulmonary function testing and during the six-hour period of testing.
The drug was administered during a M d a y open-label trial that was preceded and terminated by a two-day doubleb h d crossover test to compare metaproterenol with isoproterenol and to show if the effects of metaproterenol persisted in long-term therapy. At the beginning of the study (days 0 and 1 ) and at the end of the study ( days 59 and M ) , each patient received, in a random sequence unknown to the investigators and approximately at the same time of day, a single test dose of the 5-percent solution of metaproterenol sulfate on one day and a single test dose of the 0.5-percent solution of isoproterenol sulfate on the other day, each test dose consisting of ten inhalations of the test drug via a hand-bulb nebulizer ( DeVilbiss 40). This is approximately equivalent to 1.5 mg of metaproterenol sulfate and 0.15 mg of isoproterenol sulfate.6 After the completion of the initial crossover test, patients were placed on the continuous, open-label beatment schedule consisting of ten inhalations of metaproterenol at least four times daily, but the drug could be taken as often as every four hours if needed.
The following values for pulmonary function were measured on the four crossover testing days: forced expiratory volume (FEV), FEVI, and maximum expiratory flow rate ( MEFR ) . These measurements were made usinn a waterless &&?meter !!ones !?kottor!, before adm/+&ati o!! of the test doae (baseline), and 30 minutes. rn well as one. two, t h m , four, Bve, and aix hmra after eaeh test dose. At two-week intervals during the course of the study and also at the end d the study, global evaluations were made. Them evaluatlw took into mnsideration the mute, amount, and frequency of concurrent medtations, the adverse r e m Hans to the inhaled metaprsterenol, the patient$' general condition, and the changes in m c l s e symptoms, such rra breathlessne~, m g h , wheezing, and chest tightnem, aa well aa in egutum volume, tolerance d exercise and activity, abiltty to sleep at night, frequency and aevertty of asthmatie attadrs, s e w of well-being, and overall rrathmatic paltern. The patlenta themselves were aaked to make a final overall aaeeasment of the degree to which they kneflted from the 80 days of treatment.
The avo-point s d e of ratings used to exgreal the results of them svaluattsw was as follows: 5, excellent resulta; 4, g o d results; and 3, fair wsulfs; 2, no ek-; and 1, wrm. The pattents' responses on the two double-blind crwover teatin$ days were ~~tmilarly rated.
In the ststintical analysis of the maul@, changes from boeelfne at eaoh Hme of measurement in the crsssover tests were analyzed by a aplit-plot cmaover method (unpubbhed method, J. L. Ginemara). €Merencas between mean bwline values on different testing days were analyzed using a modification (to allow for unequal group aims) sf the method presented by Cachran and Cox,r For cliRerences between mean changer after adminbtratiaa of metaproterenol and d t e r adminiatration of iasproterenol, the standard error for the t-test, the degrees of fmedom, and the 8s-percent mfldence limits were determined for each drug at each #me sf with isoproterenol therapy.
Global E d u a t w n s
In the final crossover test (only data from the first day could be analyzed), the mean increases at onehalf, one, two, three, and six hours after metaproterenol administration exceeded those after isoproterenol administration to a statistically significant degree ( P < 0.05), ranging from 23 to 41 percent, as compared with zero to 14 percent after isopre terenol administration. The proportion of patients achieving at least a 15-percent increase in FEVI after inhalation of the 5 percent solution of metaproterenol sulfate in the initial test did not differ to a statistically significant degree from the corresponding proportion of patients with such an increase after inhalation of isoproterenol; however, in the crossover test at the end of the two-month openlabel treatment period, the proportion of patients showing an increase in FEVI of at least 15 percent was significantly greater ( P < 0.05 to P < 0.01) after inhalation of metaproterenol than after inhalation of isoproterenol at one-half, two, and six hours. On the other hand, comparison-between the initial and final crossover tests for metaproterenol showed that there was no statistically significant difference between the two tests in the proportion of patients achieving an increase in FEVI of this magnitude.
FEV. Inhalation of metaproterenol produced greater increases in FEV than inhalation of isoproterenol at all measurement times in both crossover tests. The differences between the mean changes obtained with the two drugs were not statistically significant in the initial test. As a matter of fact, only the data from the first day of the final crossover test (ie, day 59) could be evaluated, since a statistically significant difference was found between the mean changes over baseline on the two'testing days. In the final test, the increases in FEV after inhalation of metaproterenol were si@cantly greater than those after inhalation of isoproterenol at 30 minutes ( P < 0.01) and at one, two, and six hours ( P < 0.05).
MEFR. The geometric mean changes recorded after inhalation of metaproterenol were at all times greater than those after inhalation of isoproterenol in both crossover tests. A sigdcant period-time interaction during the initial tests permitted analysis of the data from day 0 only. On this day the geometric mean increase obtained after inhalation of metaproterenol was significantly greater ( P < 0.05) than that obtained after inhalation of isoproterenol at the five-hour and six-hour intervals. In the final crossover test the geometric mean changes recorded after inhalation of metaproterenol and of isoproterenol, respectively, showed no significant Werences.
Evaluation of the overall responses to test doses at the beginning of the period of study yielded mean ratings for metaproterenol (3.7) and isoproterenol (3.6) that did not differ significantly. In the final crossover test the mean score for metaproterenol (3.8) exceeded that for isoproterenol (2.9) to a highly significant degree ( P < 0.01 ) .
Interim evaluations of the patients' responses to continued treatment with the 5-percent solution of metaproterenol sulfate ranged from 3.3 during the last two weeks (weeks 7 and 8 ) to 4.3 during the third two-week period (weeks 5 and 6). The mean ratings for the first and third biweekly periods were sigdcantly higher ( P < 0.01 ) than the mean for the last two-week period.
The patients' own final appraisal of their response to 60 days of metaproterenol therapy yielded a mean score of 4.4 This came very close to our medical evaluation (4.2) .
No patient complained of any adverse reaction other than an unusual taste after the test doses of metaproterenol. One patient complained of chest tightness after a test dose of isoproterenol.
During the 60-day open trial, 13 of 27 patients occasionally complained of mild symptoms that might possibly be due to the metaproterenol used in the study. Cough was experienced by four patients, headache by three, and mild tachycardia by three; no reaction was severe enough to require the individual to stop using the drug at any time during the study. When the patients with headache and tachycardia were instructed to pause for several breaths between inhalation and to breathe slowly during each dose of ten inhalations, these symptoms disappeared. No sigdcant changes in pulse rate or in systolic or diastolic blood pressure occurred during the study with inhalation of either metaproterenol or isoproterenol. No remarkable changes in the findings from physical examination occurred during the 60-day period of treatment. No abnormal results were obtained on laboratory tests, with the exception of an elevated serum concentration of calcium in one patient at the end of the study; when checked several weeks later, the level was normal again, and the elevation was probably not due to administration of the drug.
During this 60-day trial of a $percent solution of metaproterenol sulfate administered by hand-bulb nebulizer, no significant toxicity or side effects oc- 
